Get the Stockscreener App
1.47
4.55%
-0.07
After Hours:
1.42
-0.05
-3.40%
Zura Bio Ltd stock is traded at $1.47, with a volume of 303.31K.
It is down -4.55% in the last 24 hours and up +24.05% over the past month.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
See More
Previous Close:
$1.54
Open:
$1.54
24h Volume:
303.31K
Relative Volume:
0.83
Market Cap:
$98.46M
Revenue:
-
Net Income/Loss:
$-60.36M
P/E Ratio:
-0.3345
EPS:
-4.394
Net Cash Flow:
$-15.05M
1W Performance:
+2.08%
1M Performance:
+24.05%
6M Performance:
-66.44%
1Y Performance:
-64.58%
1-Day Range:
$1.42
$1.55
1-Week Range:
$1.32
$1.6806
52-Week Range:
$0.97
$6.35
Zura Bio Ltd Stock (ZURA) Company Profile
Name
Zura Bio Ltd
Sector
Industry
Phone
858-247-0520
Address
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
1.47 | 98.46M | 0 | -60.36M | -15.05M | -4.394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
498.86 | 126.60B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
590.00 | 64.75B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
639.90 | 36.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.13 | 31.40B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
102.43 | 28.98B | 2.98B | -717.57M | -264.74M | -2.9987 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-24 | Initiated | H.C. Wainwright | Neutral |
| May-03-24 | Initiated | Piper Sandler | Overweight |
| Oct-10-23 | Initiated | Ladenburg Thalmann | Buy |
| Aug-25-23 | Initiated | Oppenheimer | Outperform |
| Jun-22-23 | Initiated | Guggenheim | Buy |
| Jun-14-23 | Initiated | Chardan Capital Markets | Buy |
| May-24-23 | Initiated | Raymond James | Strong Buy |
View All
Zura Bio Ltd Stock (ZURA) Latest News
Zura Bio Ltd Inc. (ZURA) Price Performance: The Role of Share Buybacks and Stock Splits - investchronicle.com
Do investors need to be concerned about Zura Bio Ltd (ZURA)? - uspostnews.com
Geode Capital Management LLC Increases Stake in Zura Bio Limited (NASDAQ:ZURA) - Defense World
After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain - Yahoo
ZURA overperforms with a 8.76 increase in share price - uspostnews.com
HC Wainwright Has Negative Estimate for Zura Bio Q1 Earnings - Defense World
HC Wainwright Lowers Zura Bio (NASDAQ:ZURA) Price Target to $3.00 - Defense World
ZURA stock touches 52-week low at $1.07 amid market challenges By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Zura Bio stock target to $3, keeps neutral rating - Investing.com Australia
ZURA stock touches 52-week low at $1.07 amid market challenges - Investing.com
H.C. Wainwright cuts Zura Bio stock target to $3, keeps neutral rating By Investing.com - Investing.com South Africa
Insiders' US$1.01m Investments In Red Following Zura Bio's US$21m Dip In Market Value - simplywall.st
Cantor Fitzgerald Forecasts Weaker Earnings for Zura Bio - Defense World
Zura Bio (NASDAQ:ZURA) Price Target Lowered to $10.00 at Chardan Capital - Defense World
Zura Bio Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Chardan cuts Zura Bio stock target to $10, keeps buy rating By Investing.com - Investing.com South Africa
Chardan cuts Zura Bio stock target to $10, keeps buy rating - Investing.com Australia
Guggenheim maintains Zura Bio stock buy rating, $15 target By Investing.com - Investing.com Australia
Guggenheim maintains Zura Bio stock buy rating, $15 target - Investing.com
Leerink maintains $12 target on Zura Bio stock post-earnings By Investing.com - Investing.com Australia
Leerink maintains $12 target on Zura Bio stock post-earnings - Investing.com
Zura Bio Ltd expected to post a loss of 16 cents a shareEarnings Preview - TradingView
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates - Yahoo Finance
Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday - Defense World
Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Consensus Price Target from Analysts - Defense World
Rhumbline Advisers Has $94,000 Stock Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Zura Bio to Present at the Leerink Partners Global Healthcare Conference - Yahoo Finance
Can Zura Bio's Novel Dual-Pathway Antibodies Transform Autoimmune Treatment? Key Updates Coming - Stock Titan
Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $15.80 - Defense World
Zura Bio Limited (NASDAQ:ZURA) Shares Purchased by SG Americas Securities LLC - Defense World
Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - ADVFN
ZURA stock touches 52-week low at $1.44 amid market shifts - Investing.com Nigeria
ZURA stock touches 52-week low at $1.44 amid market shifts By Investing.com - Investing.com South Africa
After losing 43% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain - Simply Wall St
Zura Bio (NASDAQ:ZURA) vs. Aptose Biosciences (NASDAQ:APTO) Critical Contrast - Defense World
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA) - MSN
Cantor Fitzgerald Predicts Zura Bio FY2025 Earnings - MarketBeat
We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth - Yahoo Finance
Barclays PLC Purchases 56,757 Shares of Zura Bio Limited (NASDAQ:ZURA) - Defense World
ZURA stock touches 52-week low at $1.97 amid market shifts - Investing.com Canada
Corporate Overview January 2025 Advancing Dual Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases - Marketscreener.com
Zura Bio Highlights Strategic Goals and Clinical Advances - TipRanks
Barclays PLC Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World
State Street Corp Increases Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World
Reversal Of Fortune For Zura Bio Insiders Who Made A US$1.01m Purchase - Simply Wall St
Zura Bio Ltd Stock (ZURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
1.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):